Thermi Acknowledges Request from FDA Regarding ThermiVa Technology

IRVING, TEXAS (July 30, 2018) – Today, the U.S. issued a public statement regarding claims by U.S. medical device manufacturers for “vaginal rejuvenation.” Here is the link to the press release and comments from the FDA Commissioner. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm615130.htm

Seven companies, including Thermi, were sent notices today requesting information/justification for specific material on company websites related to their products in this category. These companies include: Alma Lasers, BTL Aesthetics, BTL Industries, Cynosure, InMode, Sciton and Thermigen.

Thermi is committed to working closely with the FDA to address the statement released today regarding the use of ThermiVa. We look forward to resolving this issue as soon as possible, and remain committed to validating our technology through science and providing safe and effective treatments for providers and patients.

About Thermi

Thermi, an Almirall company, is the leading global developer and manufacturer of advanced temperature-controlled radiofrequency technology. Thermi systems offer versatile modalities (ThermiTight®, ThermiSmooth® Face, ThermiSmooth® Body, ThermiRase® and ThermiVa®). Our design safely provides both versatility and rapid results through controlled heating to impact positive tissue change and naturally stimulate collagen. Clinicians use Thermi technology to help address common signs of aging and/or rapid weight loss, which may include wrinkles, post-baby body, cellulite, loose skin and intimate tissue laxity, and empower people to take control over their skin, body and intimate life.

To learn more about Thermi and what its technology can offer, please visit www.thermi.com.

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics, with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of
programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers' unmet needs.

Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

For more information, please visit www.almirall.com.

**Media contact:**
VegaRun
Pam Blandon
p.blandon@vegarun.com
p: 212.453.2049 | c: 518.694.1653

**Investors & Corporate Communications contact:**
Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Tel.: +(34) 93 291 30 87